NCT01272973View on ClinicalTrials.gov

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
DiabetesDiabetes Mellitus, Type 2Healthy
Interventions
DRUG

semaglutide

Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.

DRUG

placebo

Placebo (oral) administered once daily for 10 weeks.

DRUG

semaglutide

Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.

Trial Locations (1)

14050

Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01272973 - Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter